These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 1980911

  • 1. Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity.
    Bresci G, Carrai M, Venturini G, Gambardella L.
    Int J Tissue React; 1990; 12(4):243-6. PubMed ID: 1980911
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
    Bresci G, Carrai M, Venturini G, Gambardella L.
    Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
    [Abstract] [Full Text] [Related]

  • 3. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM, Greenberg GR.
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [Abstract] [Full Text] [Related]

  • 4. [Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid].
    Maier K, Frühmorgen P, Bode JC, Heller T, von Gaisberg U, Klotz U.
    Dtsch Med Wochenschr; 1985 Mar 08; 110(10):363-8. PubMed ID: 2857633
    [Abstract] [Full Text] [Related]

  • 5. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE, Kane S.
    Rev Gastroenterol Disord; 2004 Mar 08; 4(2):86-91. PubMed ID: 15185719
    [Abstract] [Full Text] [Related]

  • 6. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H, Munakata A, Yoshida Y.
    J Gastroenterol; 1995 Nov 08; 30 Suppl 8():115-7. PubMed ID: 8563870
    [Abstract] [Full Text] [Related]

  • 7. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
    Schölmerich J, Gerok W.
    Wien Klin Wochenschr; 1986 Nov 21; 98(22):762-9. PubMed ID: 2880425
    [Abstract] [Full Text] [Related]

  • 8. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M.
    Am J Gastroenterol; 1993 Aug 21; 88(8):1188-97. PubMed ID: 8338086
    [Abstract] [Full Text] [Related]

  • 9. [Salazosulfapyridine or 5-aminosalicylic acid].
    van Hees PA.
    Ned Tijdschr Geneeskd; 1987 May 30; 131(22):931-4. PubMed ID: 2885762
    [No Abstract] [Full Text] [Related]

  • 10. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
    Bayerdörffer E, Bock H.
    Leber Magen Darm; 1988 Apr 30; 18(2):104-13. PubMed ID: 3374251
    [Abstract] [Full Text] [Related]

  • 11. [5-aminosalicylic acid treatment of ulcerative colitis during the acute phase in patients resistant or intolerant to salazopyrine].
    Cappello M, Puleo A, Calabrese A, Cipolla C, Orlando A, Gatto G, Oliva L, Cottone M.
    Recenti Prog Med; 1987 Feb 30; 78(2):76-8. PubMed ID: 2884701
    [No Abstract] [Full Text] [Related]

  • 12. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP, Wilkinson SP.
    Postgrad Med J; 1985 Dec 30; 61(722):1047-8. PubMed ID: 2869480
    [Abstract] [Full Text] [Related]

  • 13. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec 30; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 14. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I, Kawasaki M, Nagahama S, Matsuda A, Kataoka M, Kokuba Y.
    Arzneimittelforschung; 1998 Nov 30; 48(11):1091-6. PubMed ID: 9850431
    [Abstract] [Full Text] [Related]

  • 15. [Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches].
    Cigala O, Pancallo MT, Marasco A, Della Valle M.
    Clin Ter; 1990 Jul 31; 134(2):101-10. PubMed ID: 1979263
    [Abstract] [Full Text] [Related]

  • 16. [Conservative therapy of ulcerative colitis--long-term experience].
    Kölbel C, Goebell H.
    Internist (Berl); 1991 Sep 31; 32(9):530-9. PubMed ID: 1683664
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid].
    Malchow H.
    Internist (Berl); 1987 Jan 31; 28(1):14-20. PubMed ID: 2883152
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.